Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tomivosertib - Effector Therapeutics

Next Previous
X
Search
Drug Profile

Tomivosertib - Effector Therapeutics

Alternative Names: eFT-508; Tomivosertib hydrochloride

Latest Information Update: 08 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Effector Therapeutics
  • Developer eFFECTOR Therapeutics; Medpace; Merck AG; Northwestern University; Pfizer
  • Class Antineoplastics; Cyclohexanes; Imidazoles; Immunotherapies; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer; Colorectal cancer; Diffuse large B cell lymphoma; Liver cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
  • Phase I Acute myeloid leukaemia
  • No development reported Breast cancer

Most Recent Events

  • 04 Apr 2024 Efficacy and safety results from a phase II trial in Non-small cell lung cancer released by eFFECTOR Therapeutics
  • 25 Mar 2024 eFFECTOR Therapeutics plans to engage with the US FDA in second half of 2024
  • 25 Mar 2024 Effector Therapeutics plans a phase III registration trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top